Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in newly diagnosed stage III unresectable NSCLC
NCT03745222Phase 3Terminated
- Sponsor
- Celgene Corporation
- Start
- May 2019
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Tislelizumab + cCRT -> Tislelizumab, Placebo + cCRT -> Tislelizumab and Placebo + cCRT -> Placebo (3 arms). Primary endpoint: Progression-Free Survival up to 5 years. Started May 2019; status: terminated.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03745222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745222.